Prelude Therapeutics Incorporated (NASDAQ:PRLD) Insider Purchases $69,000.00 in Stock

Prelude Therapeutics Incorporated (NASDAQ:PRLD) insider Andrew Combs purchased 100,000 shares of Prelude Therapeutics stock in a transaction that occurred on Tuesday, March 25th. The shares were acquired at an average price of $0.69 per share, with a total value of $69,000.00. Following the acquisition, the insider now directly owns 480,123 shares of the company’s stock, valued at $331,284.87. This trade represents a 26.31 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Prelude Therapeutics Stock Performance

Shares of PRLD stock opened at $0.80 on Friday. Prelude Therapeutics Incorporated has a 52 week low of $0.63 and a 52 week high of $6.80. The company has a market capitalization of $44.11 million, a price-to-earnings ratio of -0.45 and a beta of 1.43. The company has a 50-day simple moving average of $0.89 and a 200 day simple moving average of $1.29.

Prelude Therapeutics (NASDAQ:PRLD) last posted its earnings results on Monday, March 10th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.11. The firm had revenue of $4.00 million during the quarter. Sell-side analysts forecast that Prelude Therapeutics Incorporated will post -1.81 EPS for the current year.

Analyst Ratings Changes

Separately, JMP Securities reiterated a “market outperform” rating and set a $4.00 target price (down from $7.00) on shares of Prelude Therapeutics in a research note on Wednesday, December 11th.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in PRLD. BNP Paribas Financial Markets acquired a new position in shares of Prelude Therapeutics in the fourth quarter valued at about $26,000. Barclays PLC boosted its holdings in Prelude Therapeutics by 86.0% in the 3rd quarter. Barclays PLC now owns 27,165 shares of the company’s stock valued at $57,000 after purchasing an additional 12,564 shares during the period. JPMorgan Chase & Co. grew its position in shares of Prelude Therapeutics by 925.0% during the 4th quarter. JPMorgan Chase & Co. now owns 61,149 shares of the company’s stock worth $78,000 after purchasing an additional 55,183 shares in the last quarter. XTX Topco Ltd bought a new position in shares of Prelude Therapeutics during the third quarter worth approximately $100,000. Finally, Deutsche Bank AG raised its position in shares of Prelude Therapeutics by 747.6% in the fourth quarter. Deutsche Bank AG now owns 123,899 shares of the company’s stock valued at $159,000 after buying an additional 109,281 shares in the last quarter. Institutional investors own 79.72% of the company’s stock.

Prelude Therapeutics Company Profile

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.